Showing 1 - 10 of 467
This paper explores different empirical strategies to examine the effect of cost sharing for prescription drugs in some dimensions of medication-related quality, namely the probability of inappropriate prescription drug use among United States seniors. Using data from 1996 to 2005, we explore...
Persistent link: https://www.econbiz.de/10008534006
This paper explores different empirical strategies to examine the effect of cost sharing for prescription drugs in some dimensions of medication-related quality, namely the probability of inappropriate prescription drug use among United States seniors. Using data from 1996 to 2005, we explore...
Persistent link: https://www.econbiz.de/10003951612
Persistent link: https://www.econbiz.de/10008648345
Persistent link: https://www.econbiz.de/10009152871
The European Union is regarded as a union of diverse territories, but this definition applies to most European Union member states, too. How best should member states manage diversity to maintain the Union? What are the main triggers for autonomy demands in a Union? This article contends that...
Persistent link: https://www.econbiz.de/10010240659
The creation of a single currency is deemed to produce further heterogeneity in regional trade, as regions differ in their exposure to trade with other European countries. It is possible to disentangle two separate effects on bilateral trade, namely the “exchange rate volatility effect”...
Persistent link: https://www.econbiz.de/10009760196
In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing). This gives rise to parallel trade (PT), a phenomenon that takes place when a patented...
Persistent link: https://www.econbiz.de/10010477153
Persistent link: https://www.econbiz.de/10012225149
This paper investigates how regulation impinges on the launch strategies of international pharmaceutical corporations for new molecules and generics across the main OECD markets during 1960-2008. Comprehensive IMS data is used to analyze the international diffusion of 845 molecules from 14...
Persistent link: https://www.econbiz.de/10009439690
Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...
Persistent link: https://www.econbiz.de/10009440020